#38 - Francisco Gonzalez-Lima, Ph.D.: Advancing Alzheimer's disease treatment and prevention – is AD actually a vascular and metabolic disease?

Episode Summary

Executive Summary: Peter Atiyah opens by explaining the podcast’s listener-supported model and then interviews neuroscientist Francesco Gonzalez Lima about Alzheimer’s disease. The conversation argues that late-onset dementia is primarily a chronic vascular/energetic disorder—driven by reduced cerebral blood flow and impaired mitochondrial respiration—rather than an amyloid-first disease, and explores prevention and treatment ideas including blood pressure control, ketogenic strategies, methylene blue, and near-infrared light.

Main Topics: Podcast funding and trust model: Atiyah explains why the show avoids ads, arguing that listener support preserves trust, honesty, and independence while funding high-quality show notes, transcripts, AMAs, and member perks. Brain organization and functional neuroanatomy: Gonzalez Lima describes the brain as a redundant, parallel, hierarchical system that computes behavior across multiple levels, contrasting it with simpler organ models and emphasizing why functional imaging matters. Reframing Alzheimer’s disease: The guest argues that late-onset Alzheimer’s is not the same disease as early-onset familial Alzheimer’s and that the field has been misled by overfocusing on amyloid beta and early-onset genetic cases. Vascular hypothesis and chronic hypoperfusion: A central thesis is that late-onset dementia reflects progressive brain hypoperfusion from vascular aging, arterial stiffness, and microvascular injury, leading to reduced energy supply to vulnerable brain networks. Mitochondrial respiration and cytochrome oxidase: The discussion links cognitive decline to impaired mitochondrial energy production, especially inhibition/downregulation of cytochrome c oxidase (complex IV), which reduces ATP generation in neurons. Therapeutic strategies: methylene blue, light, and ketosis: Potential interventions include low-dose methylene blue as a metabolic enhancer, transcranial near-infrared light to stimulate cytochrome oxidase, and ketogenic approaches to provide alternative brain fuel. Prevention, risk factors, and clinical translation: The conversation emphasizes prevention over late-stage treatment, highlighting blood pressure, atherosclerosis, heart function, trauma, and metabolic health as modifiable contributors to brain aging.

Key Arguments: Late-onset Alzheimer’s disease is a distinct entity from early-onset familial Alzheimer’s; the former is primarily age-related and vascular/energetic, not amyloid-driven. Amyloid beta is not a reliable causal explanation for most late-onset dementia because pathology often does not distinguish demented from non-demented older brains. Chronic cerebral hypoperfusion reduces oxygen delivery, which impairs mitochondrial respiration and ATP production in neurons. The posterior cingulate cortex is an early site of hypometabolism, functionally disconnecting the entorhinal cortex and hippocampal memory network. Working memory and prefrontal cortex dysfunction appear early, before more obvious limbic memory deficits. Blood pressure, arterial stiffness, carotid intima-media thickening, and atherosclerosis are important contributors to reduced brain perfusion. Cytochrome c oxidase is a key rate-limiting enzyme in oxidative phosphorylation and a plausible therapeutic target in neurodegeneration. Low-dose methylene blue can act as an electron cycler/electron donor to support mitochondrial respiration, while higher doses can become toxic or photodynamic. Near-infrared light can stimulate cytochrome oxidase and improve mitochondrial function in targeted brain regions. Ketogenic metabolism may help aging brains because ketone uptake remains available even when glucose transport becomes impaired.

Data Points: Podcast funding model: No ads; listener-supported subscription model - Atiyah explains the show relies entirely on audience support rather than advertising. Tenure at UT Austin: 27 years - Gonzalez Lima says he has been a tenured professor in Austin for 27 years. Brain energy use: ~20% of total energy expenditure - Used to illustrate the brain’s disproportionate metabolic demand relative to body weight. Brain body weight share: ~2% - Atiyah notes the brain is a small fraction of body mass but consumes a large share of energy. Blood flow decline with age: ~20% decrease from age 22 to 60 - Guest cites a decline in cerebral blood supply across adulthood. Intima-media thickness relationship: Linear relationship with cognitive decline - Carotid artery wall thickening is linked to worsening cognition. Telephone number working memory: 7 ± 2 items - Example used to explain immediate/working memory limits. Early-onset Alzheimer’s share: <1% - Referenced in discussion of PSEN1/PSEN2-type familial disease. Late-onset cases with no familial component: ~9 out of 10 - Guest states most Alzheimer’s diagnoses are not inherited. Posterior cingulate hypometabolism: Earliest functional deficit region - Identified as an early metabolic abnormality in Alzheimer’s disease. Cytochrome oxidase inhibition threshold: ~40% inhibition is lethal - Guest says organisms die when cytochrome oxidase is inhibited by about 40%. Sodium azide model deficit: Up to 30% reduction - Animal model showed cognitive impairment despite normal gross behavior. Methylene blue dose example: ~1 mg/kg - Guest suggests low-dose methylene blue as a neuroprotective concentration. Methylene blue half-life: ~12 hours - Low-dose pharmacokinetics discussed in relation to redox cycling. Transcranial light wavelength: 1064 nm - Near-infrared wavelength used to target cytochrome oxidase through the forehead. Transcranial light penetration: ~1–2% reaches cortex - Guest estimates only a small fraction of light reaches the cerebral cortex. Blood pressure target: <120/<80 mmHg - Guest cites recent clinical trial evidence favoring lower blood pressure for outcomes.

Pivotal Quotes: "This is the largest failure of the biomedical research enterprise in the world during my lifetime." — Francesco Gonzalez Lima: On the field’s inability to produce effective Alzheimer’s treatments. "What I'm saying is that there are two different diseases." — Francesco Gonzalez Lima: Distinguishing early-onset familial Alzheimer’s from late-onset dementia. "If you have a brain, you don't want to miss this episode." — Peter Atiyah: Introductory framing of the interview’s importance.

Implications: If the vascular/mitochondrial model is right, prevention should focus on brain perfusion, metabolic health, and early functional decline—not just amyloid. It also suggests repurposed metabolic therapies may deserve rigorous trials.